文献速递小儿泌尿与泌尿修复泌尿系感染

RIVUR试验再分析:风险分层识别更受益于持续抗生素预防的儿童

A Reanalysis of the RIVUR Trial Using a Risk Classification System.
PubMed 文献 · J Urol · 2017-12-02

该研究对RIVUR试验中607名膀胱输尿管反流儿童进行低风险与高风险分层再分析,比较安慰剂与持续抗生素预防组尿路感染复发风险。结果显示高风险组安慰剂尿路感染复发显著高于预防组,而低风险组两组无显著差异。

要点

  • 385名(63.9%)儿童归为低风险,217名(36.1%)为高风险。
  • 高风险组安慰剂尿路感染复发31.5% vs 预防组11.4%(p=0.001)。
  • 高风险组需治疗人数为5,低风险组为18。

核心结论

  • 高风险儿童从持续抗生素预防中获益更多,需治疗人数为5,而低风险儿童为18。

研究设计与样本

  • 从国家糖尿病、消化和肾脏疾病研究所中央数据库获取RIVUR试验607名儿童数据并再分析。

主要发现

  • 385名(63.9%)儿童归为低风险,217名(36.1%)归为高风险。
  • 低风险组安慰剂与持续抗生素预防组尿路感染复发比例无显著差异(p=0.151)。
  • 高风险组安慰剂尿路感染复发显著高于预防组(31.5% vs 11.4%,p=0.001)。
  • 高风险组安慰剂儿童2年随访期间尿路感染复发风险为预防组的3.7倍。

临床怎么用

  • 研究结果提示需细化儿童反流持续抗生素预防的适应证,支持转向基于风险的「选择性」管理策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The RIVUR (Randomized Intervention for Children with Vesicoureteral Reflux) trial showed a 50% decrease in the risk of urinary tract infection recurrence in children with reflux receiving continuous antibiotic prophylaxis. We reanalyzed the RIVUR data with the purpose of using a risk classification system to identify children who are more likely to benefit from continuous antibiotic prophylaxis. MATERIALS AND METHODS: Data from 607 children enrolled in the RIVUR trial were obtained from the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository and analyzed. We stratified these children into low and high risk categories. The proportion of children and risk of urinary tract infection recurrence in the stratified treatment groups were compared. RESULTS: Of the children 385 (63.9%) were stratified into the low risk and 217 (36.1%) into the high risk category. The proportions of children with urinary tract infection recurrence were not significantly different in the low risk category between the placebo and continuous antibiotic prophylaxis groups (p = 0.151), while urinary tract infection recurrence was significantly higher in the placebo group (31.5% vs 11.4%, p = 0.001) for high risk children. Furthermore, high risk children on placebo had a 3.7-fold increased risk of urinary tract infection recurrence during 2 years of followup compared to those on continuous antibiotic prophylaxis. CONCLUSIONS: Although the RIVUR trial concluded that children with vesicoureteral reflux benefit from continuous antibiotic prophylaxis, our reanalysis of the data demonstrates that high risk children benefit more, with a number needed to treat of 5 compared to 18 in low risk children. The clinical implications of these findings suggest a need to refine current indications for continuous antibiotic prophylaxis in children with reflux, supporting a shift toward a "selective" risk based approach for management.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Wang ZT, Wehbi E, Alam Y, et al. A Reanalysis of the RIVUR Trial Using a Risk Classification System. J Urol. 2017. PMID: 29198997. doi:10.1016/j.juro.2017.11.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。